You are here: Industry Insights > Bladder cancer

News List

Natera Selected for Circulating Tumor DNA Study in Bladder Cancer americanpharmaceuticacreview
September 25, 2017
The study will evaluate over 400 prospectively obtained plasma samples from patients who underwent treatment for bladder cancer, and whose blood was collected serially through chemotherapy and surgery.
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals fiercepharma
September 11, 2017
MADRID, Spain—Right now, Merck’s Keytruda is the only PD-1/PD-L1 med with data to show it can improve overall survival in the second-line bladder cancer setting.
NICE turns down Tecentriq in bladder cancer but suggests Roche try again for some patients fiercepharma
August 03, 2017
Roche and England’s drug cost watchdog NICE are again in an arm-wrestling match, this time over the use of Roche’s cancer drug Tecentriq for metastatic urothelial cancer.
Europe recommends Tecentriq in bladder cancer, but efficacy doubts persist pharmaphorum
July 25, 2017
The European Union’s CHMP committee recommended 11 medicines on Friday, including five orphan drugs.
UK trial for new bladder cancer therapy pharmatimes
June 28, 2017
An experimental therapy for bladder cancer in on the brink of entering Phase I clinical trials in the UK after a development pact was signed between Cancer Research UK, its commercial arm Cancer Research Technology, and Canadian biotech Sitka Biopharma.
EC Approves Opdivo for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Car americanpharmaceuticalreview
June 07, 2017
Bristol-Myers Squibb announced the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of locally advanced unresectable...
EU approves Opdivo for bladder cancer pharmatimes
June 06, 2017
Bristol-Myers Squibb’s Opdivo has picked up approval for its eighth indication in Europe, having won clearance for the treatment of a subset of patients with metastatic urothelial carcinoma (mUC).
BMS' Opdivo scores eighth approval in Europe for bladder cancer pharmafile
June 06, 2017
Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the European Commission accepts the drug for the treatment of locally-advanced unresectable or metastatic urotheli
FDA approves Merck’s bladder cancer drug europeanpharmaceuticalreview
May 25, 2017
The US Food and Drug Administration (FDA) has approved two new indications for Merck’s (known as MSD outside the US and Canada) Keytruda (pembrolizumab).
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer en-cphi.cn
May 10, 2017
Advanced urothelial carcinoma is an aggressive disease with a high rate of recurrence

Previous page 1 2 3 4 5 Next page